Description: <p><b>Itraconazole</b> — a synthetic, highly lipophilic triazole antifungal drug with substantial drug-repurposing interest in oncology. Standard abbreviations include <b>ITZ</b> and <b>ITRA</b>; Sporanox is a major brand name. Its approved pharmacologic function is inhibition of fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis. Its anticancer activity is mechanistically distinct and appears to be multitargeted, involving direct inhibition of NPC1-dependent lysosomal cholesterol export, VDAC1-dependent metabolic signaling, mTOR suppression, inhibition of VEGFR2 maturation/angiogenesis, and inhibition of Hedgehog signaling through SMO. Itraconazole remains an approved antifungal rather than an approved anticancer drug.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>↓ NPC1-mediated lysosomal cholesterol export, causing endolysosomal cholesterol accumulation and downstream disruption of growth and angiogenic signaling.</li>
<li>↓ Hedgehog signaling through inhibition of SMO trafficking/activation and downstream GLI signaling, particularly relevant to Hedgehog-dependent tumors such as basal cell carcinoma.</li>
<li>↓ Angiogenesis through impaired VEGFR2 glycosylation, trafficking and signaling, with reduced endothelial proliferation.</li>
<li>↓ mTORC1 signaling through complementary NPC1/cholesterol-trafficking and VDAC1/AMPK mechanisms.</li>
<li>↓ VDAC1-dependent mitochondrial metabolite transport, producing an increased AMP:ATP ratio, ↑ AMPK and ↓ mTOR signaling in endothelial models.</li>
<li>↓ P-glycoprotein/BCRP transporter activity and MDR-associated drug efflux, potentially contributing to chemosensitization; this is also a clinically important source of pharmacokinetic drug interactions.</li>
<li>↓ Glycolysis through the CEBPB–ENO1 axis in colorectal-cancer models, with decreases in glycolytic enzymes, glucose utilization, ECAR and tumor growth; this appears tumor- and model-dependent rather than a universal itraconazole mechanism.</li>
<li>↑ Autophagy and growth arrest in selected tumor models, frequently downstream of impaired cholesterol trafficking and AKT/mTOR signaling.</li>
<li>↑ Apoptosis and cell-cycle arrest in responsive tumor models as downstream phenotypes rather than primary direct molecular targets.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Itraconazole has nonlinear, formulation-dependent pharmacokinetics and very low aqueous solubility. Conventional capsule absolute oral bioavailability is approximately 55%, is maximal immediately after a full meal, and decreases with reduced gastric acidity or acid-suppressive therapy. Capsule and oral-solution formulations are not pharmacokinetically interchangeable; systemic exposure is generally greater with oral solution at the same dose. After repeated capsule dosing, reported steady-state Cmax values are approximately 0.5, 1.1 and 2.0 µg/mL after 100 mg once daily, 200 mg once daily and 200 mg twice daily, respectively. Itraconazole is approximately 99.8% plasma-protein bound, extensively tissue distributed, metabolized predominantly through CYP3A4, and has an active hydroxy-itraconazole metabolite. Strong CYP3A4, P-glycoprotein and BCRP inhibition produces a major drug–drug interaction burden.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Several experimentally important anticancer effects occur around the low-micromolar range, which overlaps total plasma concentrations achievable with high-dose clinical regimens, but free circulating itraconazole is far lower because protein binding approaches 99.8%. Tissue accumulation can exceed plasma concentrations, while exposure varies markedly among patients and formulations. Consequently, mechanistic plausibility is relatively strong for NPC1, VDAC1/mTOR and endothelial targets, but translation of individual in-vitro concentration-response findings should not be assumed without pharmacokinetic confirmation.</p>
<p><b>Clinical evidence status:</b> <b>Approved antifungal; oncology repurposing remains investigational.</b> Human anticancer evidence includes phase II studies in basal cell carcinoma and prostate cancer, window-of-opportunity studies in NSCLC, and small combination studies in several malignancies. A recent randomized double-blind placebo-controlled study in 60 patients with advanced epithelial ovarian cancer reported improved response and progression-free outcomes when itraconazole was added to paclitaxel/carboplatin, but this remains a small single-institution study and does not establish an approved oncology indication. A recent perioperative phase II BCC study also showed a modest reduction in tumor diameter together with decreased CD105-associated angiogenesis. Important translational limitations include substantial interpatient PK variability, CYP3A4-mediated oncology drug interactions, a boxed warning concerning congestive heart failure/negative inotropy, and rare serious hepatotoxicity.</p>
<br>
<br>
<h3>Itraconazole Mechanistic Pathway Map</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>NPC1 and lysosomal cholesterol trafficking</td>
<td>↓ NPC1 activity<br>↑ lysosomal cholesterol</td>
<td>↓ NPC1 activity<br>↑ lysosomal cholesterol</td>
<td>R/G</td>
<td>Disrupts cholesterol export and growth signaling</td>
<td>Direct itraconazole binding to NPC1 is structurally and functionally supported. This mechanism can contribute to ↓ mTOR signaling and altered membrane-associated signaling. It is not intrinsically cancer-selective.</td>
</tr>
<tr>
<td>2</td>
<td>Hedgehog SMO GLI signaling</td>
<td>↓ SMO<br>↓ GLI1<br>↓ Hedgehog signaling</td>
<td>↓ (context-dependent)</td>
<td>R/G</td>
<td>Reduced Hedgehog-dependent proliferation</td>
<td>One of the strongest tumor-directed repurposing mechanisms. Most relevant where Hedgehog signaling is oncogenic, particularly basal cell carcinoma. Clinical pharmacodynamic suppression has been demonstrated.</td>
</tr>
<tr>
<td>3</td>
<td>VEGFR2 maturation and angiogenesis</td>
<td>↓ vascular support</td>
<td>↓ VEGFR2 glycosylation<br>↓ VEGFR2 trafficking<br>↓ endothelial proliferation</td>
<td>R/G</td>
<td>Anti-angiogenic activity</td>
<td>Itraconazole impairs VEGFR2 N-glycosylation and surface trafficking in endothelial cells. This is primarily an effect on tumor-supporting vasculature rather than direct killing of malignant cells.</td>
</tr>
<tr>
<td>4</td>
<td>VDAC1 AMPK mTOR axis</td>
<td>↑ AMPK<br>↓ mTOR (model-dependent)</td>
<td>↓ VDAC1 function<br>↑ AMP:ATP<br>↑ AMPK<br>↓ mTOR</td>
<td>P/R</td>
<td>Energetic stress and suppression of anabolic signaling</td>
<td>VDAC1 is a direct itraconazole target in endothelial models. AMPK activation can occur within minutes and precedes mTOR inhibition.</td>
</tr>
<tr>
<td>5</td>
<td>mTORC1 growth signaling</td>
<td>↓ (model-dependent)</td>
<td>↓ (endothelium)</td>
<td>R/G</td>
<td>Reduced protein synthesis, proliferation and angiogenic signaling</td>
<td>Mechanistically convergent downstream effect of both NPC1-mediated cholesterol sequestration and VDAC1-mediated AMPK activation.</td>
</tr>
<tr>
<td>6</td>
<td>P-glycoprotein and multidrug resistance</td>
<td>↓ P-gp activity<br>↓ drug efflux</td>
<td>↓ P-gp activity</td>
<td>P/R</td>
<td>Chemosensitization and altered drug disposition</td>
<td>Itraconazole inhibits P-glycoprotein and can increase intracellular exposure to P-gp substrates. Therapeutically interesting for resistant tumors but clinically hazardous because the same transporter and CYP3A4 inhibition can markedly alter concomitant anticancer-drug exposure.</td>
</tr>
<tr>
<td>7</td>
<td>CEBPB ENO1 glycolysis axis</td>
<td>↓ CEBPB<br>↓ ENO1<br>↓ glycolysis<br>↓ ECAR</td>
<td>Not established</td>
<td>G</td>
<td>Reduced glycolytic metabolism and tumor growth</td>
<td>Demonstrated recently in colorectal-cancer models. ENO1, LDHA, PKM2 and GAPDH-related metabolic changes were reported, but this should currently be treated as tumor-specific rather than a universal itraconazole mechanism.</td>
</tr>
<tr>
<td>8</td>
<td>Autophagy and lysosomal stress</td>
<td>↑ autophagy (model-dependent)</td>
<td>↑ (stress-dependent)</td>
<td>G</td>
<td>Autophagic growth suppression or cell death</td>
<td>Frequently follows cholesterol-trafficking and AKT/mTOR disruption. Biological outcome varies by tumor type and can be cytostatic or cytotoxic.</td>
</tr>
<tr>
<td>9</td>
<td>Cell cycle and apoptosis</td>
<td>↑ arrest<br>↑ apoptosis (model-dependent)</td>
<td>↔ / ↑ (high exposure)</td>
<td>G</td>
<td>Reduced proliferation and programmed cell death</td>
<td>Downstream phenotype reported in multiple tumor systems rather than a single direct molecular target.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>↓ usable therapeutic window</td>
<td>↓ tolerability margin</td>
<td>G</td>
<td>PK variability, DDIs and toxicity constrain oncology use</td>
<td>Capsule absorption depends strongly on food and gastric acidity; exposure is formulation-dependent and variable. Itraconazole and hydroxy-itraconazole are potent CYP3A4 inhibitors and itraconazole inhibits P-gp/BCRP. Major concerns include numerous anticancer-drug interactions, negative inotropy/CHF risk and rare serious hepatotoxicity.</td>
</tr>
</table>
<p><b>TSF legend:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>